TIDMMTFB
RNS Number : 9893P
Motif Bio PLC
23 November 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION,
OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE
OR DISPOSE OF ANY SECURITIES IN MOTIF BIO PLC OR ANY OTHER ENTITY
IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS
DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN
CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF MOTIF BIO
PLC.
This announcement contains inside information.
Motif Bio plc
("Motif Bio" or the "Company")
23 November 2016
Motif Bio plc Announces Closing of its US$25 Million U.S.
Initial Public Offering and European Placement
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announced
today, further to the Company's announcements on Friday 18 November
2016 regarding the Company's US Initial Public Offering and
European Placing, the closing of its initial public offering of
2,438,491 American Depositary Shares ("ADSs") and 1,219,246
warrants over ADSs ("ADS Warrants") at a public offering price of
US$6.98 per ADS/ADS Warrant combination, before underwriting
discounts and commissions ("US Offering"). In addition, Motif Bio
has granted the underwriters in the US Offering an option for a
period of 30 days to purchase, at the public offering price less
underwriting discounts and commissions, up to an additional 292,618
ADSs and/or ADS Warrants to purchase 146,309 ADSs to cover any
over-allotments.
Each full ADS warrant has a per ADS exercise price of US$8.03.
The ADS warrants are exercisable immediately and have a term of
five years. The ADSs and ADS warrants are listed on The NASDAQ
Capital Market under the symbols "MTFB" and "MTFBW,"
respectively.
The US Offering is in conjunction with a placing of 22,863,428
Ordinary Shares together with 11,431,714 warrants over Ordinary
Shares (the "Ordinary Share Warrants") at a placing price per
Ordinary Share/Ordinary Share Warrant combination of 28 pence in a
European placement (the "European Placing"). Investors will be
allotted one Ordinary Share Warrant for every two Ordinary Shares
subscribed in the European Placing. The Ordinary Share Warrants
have an exercise price of 32.2 pence.
The US Offering and the European Placing (the "Fundraising") has
in aggregate, but excluding any over-allotment, raised US$25
million gross, and US$21.4 million net of expenses.
H. C. Wainwright & Co. is acting as the sole book-running
manager for the US Offering.
Zeus Capital is Nominated adviser and broker, Northland Capital
Partners is joint broker and MC Services is European placement
agent to the European Placing.
The 48,769,820 new Ordinary Shares in the Company, represented
by the 2,438,491 ADSs issued pursuant to the US Offering, and the
22,863,428 new Ordinary Shares issued pursuant to the European
Placing, were admitted to trading on the AIM market and dealings in
these Ordinary Shares commenced at 8.00am GMT this morning.
Total Voting Rights
Following Admission, the Company's issued share capital
comprises 180,643,744 Ordinary Shares with one voting right per
share. The Company does not hold any Ordinary Shares in treasury.
Therefore, this figure of 180,643,744 Ordinary Shares may be used
by Shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
A registration statement relating to these securities was
declared effective by the United States Securities and Exchange
Commission on 17 November 2016. This press release does not
constitute a prospectus and does not constitute or form part of any
offer or invitation to sell or issue, or the solicitation of an
offer to purchase or acquire, any of the ordinary shares or ADSs or
any other securities in the United States of America or in any
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Securities may
not be offered or sold in the United States of America absent
registration or an exemption from registration under the United
States Securities Act of 1933, as amended (the "Securities
Act").
The US Offering has been made only by means of a prospectus.
Copies of the prospectus relating to the offering may be obtained
from H. C. Wainwright & Co., 430 Park Avenue, New York, 10022;
Telephone: 001 212 356 0500; or email: placements@hcwco.com.
Investors may also obtain these documents at no cost by visiting
the Securities and Exchange Commission's website at
http://www.sec.gov.
For further information, please contact:
Motif Bio plc info@motifbio.com
Richard Morgan (Chairman)
Graham Lumsden (Chief
Executive Officer)
Zeus Capital Limited (NOMAD
& BROKER)
Phil Walker/Giles Balleny
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/David
Hignell
John Howes/Rob Rees (Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalized patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials (Revive 1 and Revive 2) with an
intravenous formulation of iclaprim, for the treatment of ABSSSI.
Data readout for REVIVE-1 is expected in the second quarter of 2017
and REVIVE-2 is on track for data readout in the second half of
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLBDBUUDBGLX
(END) Dow Jones Newswires
November 23, 2016 11:56 ET (16:56 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024